Sponsors (15)
The bill speeds local availability and lowers deployment costs for apheresis collection devices, improving access and convenience, at the trade-off of reduced FDA review authority that raises safety, quality, and potential public-cost risks.
Patients who need apheresis therapies will likely get faster local access when blood centers can add approved apheresis devices more quickly.
Blood centers and hospitals with multiple licensed sites or recognized accreditation can expand services more quickly, increasing supply and convenience for donors and patients.
Hospitals and blood-collection operators may face lower administrative costs and faster deployment of collection devices due to shorter FDA review timelines for routine supplemental BLAs.
Patients receiving apheresis therapies face higher risk of site-specific safety lapses if a faster 30-day automatic approval period is insufficient to catch problems.
Limiting FDA's ability to delay or more thoroughly review supplemental approvals could reduce regulatory scrutiny and produce uneven oversight and product quality across locations.
Taxpayers and patients could bear financial costs if expedited expansion results in recalls or corrective actions that require public-health responses or reimbursements.
Based on analysis of 2 sections of legislative text.
Requires HHS to set up an expedited FDA approval process to add apheresis collection devices at new blood center locations, with 30-day approvals for qualifying applicants.
Requires the HHS Secretary to create an expedited FDA approval pathway for supplemental biologics license applications from blood center owners/operators who want to add an apheresis collection device at a site not previously licensed for that device. The Department must set up the procedure within 180 days and generally approve qualifying supplemental applications within 30 days unless there is a safety or systemic-compliance problem. The expedited pathway applies to applicants that already hold a BLA for at least one site and either operate three or more FDA-registered locations under that license or are accredited and in good standing by an HHS-approved accreditation organization. The goal is to speed deployment of lifesaving apheresis collection capacity while preserving safety standards.
Official title: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to establish an expedited process for the approval of certain biologics license application supplements for blood centers, and for other purposes.
Introduced October 17, 2025 by Tony Wied · Last progress October 17, 2025